Search Results - Sorin Visanica

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

    Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Franc... by Lionel Adès, Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Virginie Eclache, Jacques Delaunay, Didier Bouscary, Sorin Visanica, Pascal Turlure, Agnès Guerci Bresler, Marie-Paule Cabrol, Anne Banos, Michel Blanc, Norbert Vey, Alain Delmer, Eric Wattel, Sylvie Chevret, Pierre Fenaux

    Published 2012-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

    Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia by Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot

    Published 2022-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: